{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T04:04:59Z","timestamp":1751601899088,"version":"3.41.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-025-02793-3","type":"journal-article","created":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:42:45Z","timestamp":1750174965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Entinostat and novel analogs: preclinical evidence for anti-proliferative activity in adult T-cell leukemia\/lymphoma"],"prefix":"10.1007","volume":"42","author":[{"given":"Sajad","family":"Goudarzi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Nasiri Sarvi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Ayatollahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razieh","family":"Ghodsi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeinab","family":"Noroozi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Reza","family":"Keramati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh B.","family":"Rassouli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,17]]},"reference":[{"issue":"5","key":"2793_CR1","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1111\/cas.14869","volume":"112","author":"K Nosaka","year":"2021","unstructured":"Nosaka K, Matsuoka M. Adult T-cell leukemia-lymphoma as a viral disease: Subtypes based on viral aspects. Cancer Sci. 2021;112(5):1688\u201394.","journal-title":"Cancer Sci"},{"key":"2793_CR2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1177\/0956462416684461","volume":"28","author":"PD Oliveira","year":"2017","unstructured":"Oliveira PD, de Carvalho RF, Bittencourt AL. Adult T-cell leukemia\/lymphoma in South and Central America and the Caribbean: Systematic search and review. Int J STD AIDS. 2017;28:217\u201328.","journal-title":"Int J STD AIDS"},{"issue":"10","key":"2793_CR3","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1111\/cas.15097","volume":"112","author":"S Ito","year":"2021","unstructured":"Ito S, Iwanaga M, Nosaka K, Imaizumi Y, Ishitsuka K, Amano M, Utsunomiya A, Tokura Y, Watanabe T, Uchimaru K, Tsukasaki K. Epidemiology of adult T-cell leukemia-lymphoma in Japan: An updated analysis, 2012\u20132013. Cancer Sci. 2021;112(10):4346\u201354.","journal-title":"Cancer Sci"},{"issue":"10","key":"2793_CR4","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.3390\/biom13101543","volume":"13","author":"S Nakahata","year":"2023","unstructured":"Nakahata S, Enriquez-Vera D, Jahan MI, Sugata K, Satou Y. Understanding the immunopathology of HTLV-1-associated adult T-cell leukemia\/lymphoma: A comprehensive review. Biomolecules. 2023;13(10):1543.","journal-title":"Biomolecules"},{"key":"2793_CR5","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.812016","volume":"9","author":"C Rosadas","year":"2022","unstructured":"Rosadas C, Taylor GP. HTLV-1 and co-infections. Front Med. 2022;9: 812016.","journal-title":"Front Med"},{"issue":"3","key":"2793_CR6","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1111\/ejh.13728","volume":"108","author":"K Nosaka","year":"2022","unstructured":"Nosaka K, Crawford B, Yi J, Kuan W, Matsumoto T, Takahashi T. Systematic review of survival outcomes for relapsed or refractory adult T-cell leukemia-lymphoma. Eur J Haematol. 2022;108(3):212\u201322.","journal-title":"Eur J Haematol"},{"issue":"2","key":"2793_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12325-018-0658-4","volume":"35","author":"O Hermine","year":"2018","unstructured":"Hermine O, Ramos JC, Tobinai K. A review of new findings in adult T-cell leukemia-lymphoma: A focus on current and emerging treatment strategies. Adv Ther. 2018;35(2):135\u201352.","journal-title":"Adv Ther"},{"key":"2793_CR8","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.3389\/fmicb.2020.01207","volume":"11","author":"K Tsukasaki","year":"2020","unstructured":"Tsukasaki K, Mar\u00e7ais A, Nasr R, Kato K, Fukuda T, Hermine O, Bazarbachi A. Diagnostic approaches and established treatments for adult T cell leukemia lymphoma. Front Microbiol. 2020;11:1207.","journal-title":"Front Microbiol"},{"issue":"18","key":"2793_CR9","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1111\/febs.14492","volume":"285","author":"EW Harhaj","year":"2018","unstructured":"Harhaj EW, Giam CZ. NF-kappaB signaling mechanisms in HTLV-1-induced adult T-cell leukemia\/lymphoma. FEBS J. 2018;285(18):3324\u201336.","journal-title":"FEBS J"},{"issue":"43","key":"2793_CR10","doi-asserted-by":"crossref","first-page":"26270","DOI":"10.1074\/jbc.M115.684746","volume":"290","author":"MA Cherian","year":"2015","unstructured":"Cherian MA, Baydoun HH, Al-Saleem J, Shkriabai N, Kvaratskhelia M, Green P, Ratner L. Akt pathway activation by human T-cell leukemia virus type 1 Tax oncoprotein. J Biol Chem. 2015;290(43):26270\u201381.","journal-title":"J Biol Chem"},{"issue":"6","key":"2793_CR11","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.coviro.2013.08.010","volume":"3","author":"M Matsuoka","year":"2013","unstructured":"Matsuoka M, Yasunaga J. Human T-cell leukemia virus type 1: replication, proliferation and propagation by Tax and HTLV-1 bZIP factor. Curr Opin Virol. 2013;3(6):684\u201391.","journal-title":"Curr Opin Virol"},{"issue":"2","key":"2793_CR12","first-page":"6","volume":"2","author":"C Nicot","year":"2015","unstructured":"Nicot C. HTLV-I Tax-mediated inactivation of cell cycle checkpoints and DNA repair pathways contribute to cellular transformation: \u201cA random mutagenesis model.\u201d J Cancer Sci. 2015;2(2):6.","journal-title":"J Cancer Sci"},{"issue":"1","key":"2793_CR13","first-page":"88","volume":"6","author":"R Torshizi","year":"2017","unstructured":"Torshizi R, Ghayour Karimani E, Etminani K, Akbarin MM, Jamialahmadi K, Shirdel A, Rahimi H, Allahyari A, Golabpour A, Rafatpanah H. Altered expression of cell cycle regulators in adult T-cell leukemia\/ lymphoma patients. Rep Biochem Mol Biol. 2017;6(1):88\u201394.","journal-title":"Rep Biochem Mol Biol"},{"issue":"7","key":"2793_CR14","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/j.1460-2075.1996.tb00505.x","volume":"15","author":"T Suzuki","year":"1996","unstructured":"Suzuki T, Kitao S, Matsushime H, Yoshida M. HTLV-1 Tax protein interacts with cyclin-dependent kinase inhibitor p16INK4A and counteracts its inhibitory activity towards CDK4. EMBO J. 1996;15(7):1607\u201314.","journal-title":"EMBO J"},{"key":"2793_CR15","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1742-4690-2-54","volume":"2","author":"K Fraedrich","year":"2005","unstructured":"Fraedrich K, M\u00fcller B, Grassmann R. The HTLV-1 Tax protein binding domain of cyclin-dependent kinase 4 (CDK4) includes the regulatory PSTAIRE helix. Retrovirology. 2005;2:54.","journal-title":"Retrovirology"},{"issue":"14","key":"2793_CR16","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/onc.2009.498","volume":"29","author":"YM Kim","year":"2010","unstructured":"Kim YM, Geiger TR, Egan D, Sharma N, Nyborg JK. The HTLV-1 Tax protein cooperates with phosphorylated CREB, TORC2, and p300 to activate CRE-dependent cyclin D1 transcription. Oncogene. 2010;29(14):2142\u201352.","journal-title":"Oncogene"},{"key":"2793_CR17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3389\/fmicb.2018.00285","volume":"9","author":"S Fochi","year":"2018","unstructured":"Fochi S, Mutascio S, Bertazzoni U, Zipeto D, Romanelli MG. HTLV deregulation of the NF-kappaB pathway: An update on Tax and antisense proteins role. Front Microbiol. 2018;9:285.","journal-title":"Front Microbiol"},{"issue":"2","key":"2793_CR18","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.canlet.2011.11.030","volume":"317","author":"K Ishitsuka","year":"2012","unstructured":"Ishitsuka K, Kunami N, Katsuya H, Nogami R, Ishikawa C, Yotsumoto F, Tanji H, Mori N, Takeshita M, Miyamoto S, Tamura K. Targeting Bcl-2 family proteins in adult T-cell leukemia\/lymphoma: in vitro and in vivo effects of the novel Bcl-2 family inhibitor ABT-737. Cancer Lett. 2012;317(2):218\u201325.","journal-title":"Cancer Lett"},{"issue":"2","key":"2793_CR19","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/ijc.29726","volume":"138","author":"M Witzens-Harig","year":"2016","unstructured":"Witzens-Harig M, Giaisi M, K\u00f6hler R, Krammer PH, Li-Weber M. HTLV-1-associated adult T cell leukemia is highly susceptible to Navitoclax due to enhanced Bax expression. Int J Cancer. 2016;138(2):507\u201314.","journal-title":"Int J Cancer"},{"issue":"6","key":"2793_CR20","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/sj.cdd.4401233","volume":"10","author":"JJ Luke","year":"2003","unstructured":"Luke JJ, Van De Wetering CI, Knudson CM. Lymphoma development in Bax transgenic mice is inhibited by Bcl-2 and associated with chromosomal instability. Cell Death Differ. 2003;10(6):740\u20138.","journal-title":"Cell Death Differ"},{"key":"2793_CR21","doi-asserted-by":"crossref","first-page":"19571","DOI":"10.1039\/C9RA02985K","volume":"9","author":"F Yang","year":"2019","unstructured":"Yang F, Zhao N, Ge D, Chen Y. Next-generation of selective histone deacetylase inhibitors. RSC Adv. 2019;9:19571.","journal-title":"RSC Adv"},{"issue":"2","key":"2793_CR22","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s12276-020-0382-4","volume":"52","author":"SY Park","year":"2020","unstructured":"Park SY, Kim JS. A short guide to histone deacetylases including recent progress on class II enzymes. Exp Mol Med. 2020;52(2):204\u201312.","journal-title":"Exp Mol Med"},{"issue":"4","key":"2793_CR23","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3390\/cancers13040634","volume":"13","author":"R Jenke","year":"2021","unstructured":"Jenke R, Rebing N, Hansen FK, Aigner A, B\u00fcch T. Anticancer therapy with HDAC inhibitors: Mechanism-based combination strategies and future perspectives. Cancers. 2021;13(4):634.","journal-title":"Cancers"},{"key":"2793_CR24","doi-asserted-by":"crossref","first-page":"1351e1356","DOI":"10.1038\/sj.onc.1210204","volume":"26","author":"P Marks","year":"2007","unstructured":"Marks P. Discovery and development of SAHA as an anticancer agent. Oncogene. 2007;26:1351e1356.","journal-title":"Oncogene"},{"key":"2793_CR25","doi-asserted-by":"crossref","first-page":"1400e1410","DOI":"10.1002\/ijc.23243","volume":"122","author":"X Qian","year":"2008","unstructured":"Qian X, Ara G, Mills E, LaRochelle WJ, Lichenstein HS, Jeffers M. Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancer. Int J Cancer. 2008;122:1400e1410.","journal-title":"Int J Cancer"},{"key":"2793_CR26","first-page":"4767e4773","volume":"21","author":"JP Laubach","year":"2015","unstructured":"Laubach JP, Moreau P, San-Miguel JF, Richardson PG. Panobinostat for the treatment of multiple myeloma. Clin Cancer Res. 2015;21:4767e4773.","journal-title":"Clin Cancer Res"},{"key":"2793_CR27","doi-asserted-by":"crossref","first-page":"759e768","DOI":"10.1158\/1535-7163.MCT-07-2026","volume":"7","author":"M Fournel","year":"2008","unstructured":"Lu AH, Zhou NZ, Robert MF. MGCD0103, a novel isotype-selective histone deacetylase inhibitor, has broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Therapeut. 2008;7:759e768.","journal-title":"Mol Cancer Therapeut."},{"key":"2793_CR28","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1186\/s12885-021-08973-4","volume":"21","author":"N Masuda","year":"2021","unstructured":"Masuda N, Tamura K, Yasojima H, Shimomura A, Sawaki M, Lee MJ, Yuno A, Trepel J, Kimura R, Nishimura Y, Saji S, Iwata H. Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer. BMC Cancer. 2021;21:1269.","journal-title":"BMC Cancer"},{"issue":"8","key":"2793_CR29","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1080\/15384101.2018.1464849","volume":"17","author":"B Wang","year":"2018","unstructured":"Wang B, Lyu H, Pei S, Song D, Ni J, Liu B. Cladribine in combination with entinostat synergistically elicits anti-proliferative\/anti-survival effects on multiple myeloma cells. Cell Cycle. 2018;17(8):985\u201396.","journal-title":"Cell Cycle"},{"key":"2793_CR30","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.canlet.2017.10.023","volume":"414","author":"XP Huang","year":"2018","unstructured":"Huang XP, Li X, Situ MY, Huang LY, Wang JY, He TC, Yan QH, Xie XY, Zhang YJ, Gao YH, Li YH, Rong TH, Wang MR, Cai QQ, Fu JH. Entinostat reverses cisplatin resistance in esophageal squamous cell carcinoma via down-regulation of multidrug resistance gene 1. Cancer Lett. 2018;414:294\u2013300.","journal-title":"Cancer Lett"},{"issue":"36","key":"2793_CR31","doi-asserted-by":"crossref","first-page":"25306","DOI":"10.1074\/jbc.M114.557546","volume":"289","author":"J Shin","year":"2014","unstructured":"Shin J, Carr A, Corner GA, Togel L, D\u00e1valos-Salas M, Tran H, Chueh AC, Al-Obaidi S, Chionh F, Ahmed N, Buchanan DD, Young JP, Malo MS, Hodin RA, Arango D, Sieber OM, Augenlicht LH, Dhillon AS, Weber TK, Mariadason JM. The intestinal epithelial cell differentiation marker intestinal alkaline phosphatase (ALPi) is selectively induced by histone deacetylase inhibitors (HDACi) in colon cancer cells in a Kruppel-like factor 5 (KLF5)-dependent manner. J Biol Chem. 2014;289(36):25306\u201316.","journal-title":"J Biol Chem"},{"key":"2793_CR32","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2019.116583","volume":"232","author":"Z Zhou","year":"2019","unstructured":"Zhou Z, Fang Q, Li P. Entinostat combined with Fludarabine synergistically enhances the induction of apoptosis in TP53 mutated CLL cells via the HDAC1\/HO-1 pathway. Life Sci. 2019;232: 116583.","journal-title":"Life Sci"},{"key":"2793_CR33","doi-asserted-by":"crossref","first-page":"W611","DOI":"10.1093\/nar\/gkac305","volume":"50","author":"K Sch\u00f6ning-Stierand","year":"2022","unstructured":"Sch\u00f6ning-Stierand K, Diedrich K, Ehrt C, Flachsenberg F, Graef J, Sieg J, Penner P, Poppinga M, Ungeth\u00fcm A, Rarey M. ProteinsPlus: a comprehensive collection of web-based molecular modeling tools. Nucleic Acids Res. 2022;50:W611\u20135.","journal-title":"Nucleic Acids Res"},{"key":"2793_CR34","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.1021\/acs.jcim.0c01095","volume":"60","author":"F Flachsenberg","year":"2020","unstructured":"Flachsenberg F, Meyder A, Sommer K, Penner P, Rarey M. A consistent scheme for gradient-based optimization of protein\u2013ligand poses. J Chem Inf Mod. 2020;60:6502\u201322.","journal-title":"J Chem Inf Mod"},{"key":"2793_CR35","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s10822-023-00522-4","volume":"37","author":"K Diedrich","year":"2023","unstructured":"Diedrich K, Krause B, Berg O, Rarey M. PoseEdit: enhanced ligand binding mode communication by interactive 2D diagrams. J Comput Aided Mol Des. 2023;37:491\u2013503.","journal-title":"J Comput Aided Mol Des"},{"issue":"9","key":"2793_CR36","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1021\/ml100164p","volume":"1","author":"K Stierand","year":"2010","unstructured":"Stierand K, Maass PC, Rarey M. Drawing the PDB - protein-ligand complexes in two dimensions. Med Chem Let. 2010;1(9):540\u20135.","journal-title":"Med Chem Let"},{"issue":"29","key":"2793_CR37","first-page":"e202201239","volume":"7","author":"N Omidkhah","year":"2022","unstructured":"Omidkhah N, Eisvand F, Hadizadeh F, Zarghi A, Ghodsi R. Synthesis, cytotoxicity, pan-HDAC inhibitory activity and docking study of N-(2-Aminophenyl)-2-arylquinoline-4- and N-(2-Aminophenyl)-2-arylbenzo[h]quinoline-4-carboxamides. Chem Select. 2022;7(29):e202201239.","journal-title":"Chem Select"},{"key":"2793_CR38","doi-asserted-by":"crossref","first-page":"133599","DOI":"10.1016\/j.molstruc.2022.133599","volume":"1267","author":"N Omidkhah","year":"2022","unstructured":"Omidkhah N, Hadizadeh F, Abnous K, Ghodsi R. Synthesis, structure activity relationship and biological evaluation of a novel series of quinoline\u2013based benzamide derivatives as anticancer agents and histone deacetylase (HDAC) inhibitors. J Mol Struct. 2022;1267:133599.","journal-title":"J Mol Struct"},{"issue":"1","key":"2793_CR39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1089\/ars.2014.5863","volume":"23","author":"AC Chueh","year":"2015","unstructured":"Chueh AC, Tse JW, Togel L, Mariadason JM. Mechanisms of histone deacetylase inhibitor-regulated gene expression in cancer cells. Antioxid Redox Signal. 2015;23(1):66\u201384.","journal-title":"Antioxid Redox Signal"},{"key":"2793_CR40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/CCO.0b013e32833d5954","volume":"22","author":"A Copeland","year":"2010","unstructured":"Copeland A, Buglio D, Younes A. Histone deacetylase inhibitors in lymphoma. Curr Opin Oncol. 2010;22:431\u20136.","journal-title":"Curr Opin Oncol"},{"issue":"10","key":"2793_CR41","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.exphem.2011.07.002","volume":"39","author":"A Jona","year":"2011","unstructured":"Jona A, Khaskhely N, Buglio D, Shafer JA, Derenzini E, Bollard CM, Medeiros LJ, Ill\u00e9s A, Ji Y, Younes A. The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors. Exp Hematol. 2011;39(10):1007-1017.e1.","journal-title":"Exp Hematol"},{"issue":"6","key":"2793_CR42","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1038\/leu.2012.366","volume":"27","author":"L Zhou","year":"2013","unstructured":"Zhou L, Ruvolo V, Mcqueen T, Chen W, Samudio IJ, Conneely O, Konopleva M, Andreeff M. HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML. Leukemia. 2013;27(6):1358\u201368.","journal-title":"Leukemia"},{"key":"2793_CR43","doi-asserted-by":"crossref","first-page":"113169","DOI":"10.1016\/j.ejmech.2021.113169","volume":"215","author":"A Singh","year":"2021","unstructured":"Singh A, Chang TY, Kaur N, Hsu KC, Yen Y, Lin TE, Lai MJ, Lee SB, Liou JP. CAP rigidification of MS-275 and chidamide leads to enhanced antiproliferative effects mediated through HDAC1, 2 and tubulin polymerization inhibition. Eur J Med Chem. 2021;215:113169.","journal-title":"Eur J Med Chem"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02793-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-025-02793-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-025-02793-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T08:39:31Z","timestamp":1751531971000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-025-02793-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,17]]},"references-count":43,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["2793"],"URL":"https:\/\/doi.org\/10.1007\/s12032-025-02793-3","relation":{},"ISSN":["1559-131X"],"issn-type":[{"type":"electronic","value":"1559-131X"}],"subject":[],"published":{"date-parts":[[2025,6,17]]},"assertion":[{"value":"12 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}],"article-number":"270"}}